An interventional study of MG1111 in Varicella Zoster Virus Infection, sponsored by GC Biopharma Corp. Status unknown. Open to participants aged 12 Months to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-23.
Sponsored by GC Biopharma Corp · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this bridging study is to assess the safety and immunogenicity of BARYCELA inj. in healthy Vietnamese children aged between 12 months to 12 years. The main questions it aims to answer are:
Participants will be administered subcutaneously with a single dose(0.5 mL dose) of the BARYCELA inj.(MG1111) on the upper arm (brachia lateral).
180 studies on the registry are indexed under Chickenpox; 28 are open to participants now.
This study's planned enrollment of 250 is below the median of 475 across 149 interventional studies indexed under Chickenpox.
Browse Chickenpox studies →GC Biopharma Corp is the lead sponsor of 16 studies on the registry; 6 are open to participants now.
Compared within Chickenpox, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Varicella Zoster Virus Infection. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be administered subcutaneously with a single dose(0.5 mL dose) of the BARYCELA inj.(MG1111) on the upper arm (brachia lateral).
Biological: MG1111
BARYCELA inj.
Safety of BARYCELA inj.: Solicited local and systemic reactogenicity
The incidence and severity of immediate solicited local and systemic reactogenicity
Time frame: within 30-minute post vaccination
Safety of BARYCELA inj.: The incidence and severity of solicited local and systemic AEs
The incidence and severity of solicited local and systemic AEs
Time frame: during 7 days post vaccination
Safety of BARYCELA inj.: Incidence and severity of unsolicited AEs
The incidence and severity of unsolicited AEs
Time frame: during 42 days post vaccination
Safety of BARYCELA inj.: Incidence of adverse event of special interest
The incidence of AE of Special Interest (AESI): varicella-like rash.
Time frame: during 42 days post vaccination
Safety of BARYCELA inj.: Vital signs
Vital signs
Time frame: Day0(Pre vaccination), 42 days post vaccination
Safety of BARYCELA inj.: Body temperature
Body temperature; measured according to standard of care and thermometer instructions.
Time frame: Day0(Pre vaccination), 42 days post vaccination
Safety of BARYCELA inj.: Complete physical examination
Complete physical examination; performed at Screening/Enrollment (Day 0) and Final Visit(Day 42).
Time frame: Day0(Pre vaccination), 42 days post vaccination
Safety of BARYCELA inj.: Symptom-directed physical examination
Symptom-directed physical examination (if any symptoms); performed at other timepoints as indicated to assess changes from Screening
Time frame: Day0(Pre vaccination), during 42 days post vaccination
Immunogenicity of BARYCELA inj.: Geometric Mean Titer (GMT)
Geometric Mean Titer (GMT) of antibody titer measured with gpELISA
Time frame: Prior to IP administration and 42 days post vaccination
Immunogenicity of BARYCELA inj.: Geometric Mean Fold Rise (GMFR)
Geometric Mean Fold Rise (GMFR)
Time frame: Prior to IP administration and 42 days post vaccination
No study locations are listed for this record.
Start is estimated for Feb 2023; primary completion for Apr 2023, 2 months later.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MG1111